ABBV AbbVie Inc. Common Stock
NYSE · Biotechnology · View on SEC EDGAR ↗ 10-K/10-Q Aug 3, 2026ABBV Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
ABBV Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About AbbVie Inc. Common Stock Company overview from Wikipedia
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'.
History
AbbVie was formed in 2012 as a corporate spin-off from Abbott Laboratories. It became a public company in January 2013.
In January 2014, the company acquired ImmuVen, a startup incubated at the University of Illinois Urbana-Champaign and focused on biotherapeutics to treat cancer, infectious disease, and autoimmune disorders.
In September 2014, AbbVie and Infinity Pharmaceuticals entered into a collaboration to develop and commercialize duvelisib, Infinity's PI3K inhibitor for the treatment of patients with cancer. On the same day, AbbVie and Calico entered into a research and development (R&D) collaboration intended to discover, develop and bring to market new therapies for patients with aging-associated diseases including neurodegeneration and cancer. California Life Company, operating as Calico, is an Alphabet Inc. subsidiary focused on aging and age-related diseases, and led by former Genentech chairman and CEO of Arthur D. Levinson and former Genentech EVP and chief medical officer Hal V. Barron (who subsequently left the company).
In October 2014, AbbVie ended its efforts to acquire Shire, which would have been one of the largest mergers and acquisitions (M&A) deals of that year and one of the largest tax inversions in history, due to changes in the US tax code by the US Treasury; AbbVie had to pay a $1.6 billion breakup fee.
In May 2015, AbbVie acquired oncology firm Pharmacyclics and its treatment for blood cancers, ibrutinib; AstraZeneca had also been bidding to acquire Pharmacyclics. The Pharmacyclics name was retained, and it operated as a subsidiary of AbbVie from its previous Sunnyvale, California headquarters until the consolidation of AbbVie Bay Area sites in a new building in South San Francisco. In June 2015, AbbVie and Halozyme Therapeutics entered into a global collaboration and licensing agreement to develop and commercialize products that combine AbbVie's treatments and Halozyme's ENHANZE drug-delivery technology, this was terminated in November 2016.
In February 2016, AbbVie and Cambridge, Massachusetts-based Synlogic announced a multi-year R&D collaboration. Synlogic is a synthetic biology company built on research from the labs of James Collins and Tim Lu at MIT. As part of the collaboration, AbbVie is getting worldwide rights to Synlogic's probiotic-based technology for treating inflammatory bowel disease, and the research teams will focus on Crohn's disease and ulcerative colitis.
In April 2016, the company announced it would acquire Stemcentrx for up to $9.8 billion. A day later, the company announced an expansion of a two and a half-year-old cystic fibrosis deal with Galapagos NV, potentially doubling milestone payments to $600 million.
Also in April 2016, the company partnered with the University of Chicago to investigate several areas of oncology: breast, lung, prostate, colorectal and hematological cancers.
Also in April 2016, the company announced it would co-commercialize Argenx's preclinical immunotherapy, ARGX-115. ARGX-115 is a first-in-class immunotherapy targeting GARP (glycoprotein A repetitions predominant), a membrane protein believed to enhance the immunosuppressive effects of T cells. The company also announced a deal to co-develop/commercialize at least one of CytomX Probody's conjugates against CD71 (transferrin receptor 1).
In June 2019, AbbVie announced it would acquire Irish-based Allergan plc for about $63 billion; however the transaction was not structured as a tax inversion; AbbVie remained legally domiciled in the U.S. for tax purposes. To gain FTC approval, the company divested Allergan's late-stage gastrointestinal candidate brazikumab to AstraZeneca as well as two pancreatic replacement enzymes, Zenpep and Viokace, to Nestlé. In July 2019, the company announced it would acquire Mavupharma, boosting its cancer drug pipeline.
In March 2020, during the COVID-19 pandemic, AbbVie announced plans to evaluate the Kaletra/Aluvia HIV medicine as possible COVID-19 treatment. The company entered into various partnerships with health authorities in different countries to investigate the efficacy of the medication. However, the first non-blinded, randomized trial found the drug not useful to treat severe COVID-19. The Israeli government announced that it would force AbbVie to license its patents for Kaletra, the brand name of lopinavir/ritonavir, a fixed dose combination medication for the treatment and prevention of HIV/AIDS which was also thought to have some applicability to fighting COVID-19. In response, AbbVie announced that it would cease enforcing its patents on the drug entirely.
In May 2021, Allergan Aesthetics announced the acquisition of Soliton. In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma.
In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118. In October, the company acquired DJS Antibodies for $225 million, giving it access to an experimental drug for an aggressive lung disease as well as technology to develop certain antibody medicines. In January 2023, Humira began facing competition from biosimilars.
In February 2024, AbbVie acquired ImmunoGen for $10.1 billion, aiming to expedite its entry into the ovarian cancer treatment market with ImmunoGen's drug Elahere. In the same month, AbbVie and Tentarix Biotherapeutics announced the beginning of a long-term collaboration in the discovery and development of opportunistic, multi-specific biological candidates in oncology and immunology. AbbVie provides expertise in these areas, and will also provide Tentarix with option advances worth $64 million for two programs, and Tentarix will provide its patented Tentarix Tentacles™platform. AbbVie also received an option to purchase the software in full.
In March 2024, the company announced it would acquire Landos Biopharma for over $200 million. In June 2024, Robert Michael replaced Richard Gonzalez as CEO of AbbVie. Gonzalez became the executive chairman. In August 2024, AbbVie acquired neuroscience drugmaker Cerevel Therapeutics for $8.7 billion, in an attempt to expand its drug pipeline. In September 2024, AbbVie filed a lawsuit against BeiGene accusing it of stealing trade secrets to develop a competing therapy to treat blood and bone marrow cancers related to the growth of "B cells" after BeiGene hired a former longtime senior AbbVie scientist. In October 2024, AbbVie acquired Aliada Therapeutics for $1.4 billion to expand its neuroscience pipeline.
In January 2025, AbbVie acquired Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune area, for $200 million. In the same month, AbbVie announced a $1.64 billion partnership with Neomorph to develop new molecular glue degraders for multiple targets across oncology and immunology, as well as a $1 billion partnership with Simcere Zaiming to develop an investigational drug candidate for multiple myeloma. In May 2025, AbbVie entered into a collaboration and license option deal with ADARx Pharmaceuticals to develop a new type of RNA technology for disease areas like neuroscience, immunology, and oncology. In August 2025, AbbVie acquired Bretisilocin, which is under development for the treatment of major depressive disorder, from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.
In January 2026, AbbVie struck a deal with the Trump administration to invest $100 billion in its US operations over the next 10 years and lower Medicaid prices. In exchange, the administration exempted AbbVie from tariffs and future pricing mandates.
Acquisition history
Major products
The company's major products are: Humira (adalimumab) ($9 billion in 2024 revenues, 16% of total revenues), approved to treat autoimmune diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, crohn's disease and ulcerative colitis and administered via injection; Skyrizi (Risankizumab) ($11.7 billion in 2024 revenues, 21% of total revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases; Rinvoq (Upadacitinib) ($6.0 billion in 2023 revenues, 11% of total revenues), used to treat arthritis; and Botox ($6.0 billion in 2024 revenues, 11% of total revenues). Its other major products include Imbruvica (Ibrutinib) to treat cancer ($3.3 billion in 2024 revenues), Vraylar (Cariprazine) to treat schizophrenia and bipolar disorder ($3.3 billion in 2024 revenues), Venclexta (Venetoclax) to treat leukemia and lymphoma ($2.6 billion in 2024 revenues), Mavyret (Glecaprevir/pibrentasvir) to treat Hepatitis C ($1.3 billion in 2024 revenues), and Epkinly (epcoritamab), a blood-cancer therapy developed in partnership with Genmab ($0.1 billion in 2024 revenues). The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis. The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev (Foscarbidopa/foslevodopa) and tavapadon.
Legal issues
Anti-competitive practices
AbbVie has been accused of using anti-competitive patent thickets to prevent potentially cheaper biosimilars from entering the market. AbbVie and Alvotech, filed lawsuits against each other regarding a Humira biosimilar introduced by Alvotech. The lawsuits were settled out of court in 2022. Forest Laboratories, a subsidiary of AbbVie, was accused of using unlawful deals to prevent generic versions of its Alzheimer's disease drug, Namenda, from entering the market. In 2018, AbbVie agreed to pay $25 million to resolve allegations that it used kickback schemes to promote its cholesterol drug TriCor (fenofibrate). In 2020, AbbVie agreed to pay $24 million to resolve allegations that it used kickback schemes to promote Humira using "nurse ambassadors".
A report from the House Oversight and Reform Committee found that "AbbVie pursued a variety of tactics to increase drug sales while raising prices for Americans, including exploiting the patent system to extend its market monopoly, abusing orphan drug protections to further block competition, and engaging in anticompetitive pricing practices". Pursuant to the Inflation Reduction Act, the price of Imbruvica was reduced by 38%, to $9,319 per month, effective in 2026.
Tax avoidance
In June 2021, the United States Senate Finance Committee, under Chair Ron Wyden (D-OR), began an investigation to determine if the company took advantage of loopholes in the Tax Cuts and Jobs Act of 2017 to significantly reduce its tax liability. In a letter to AbbVie CEO Richard Gonzalez, Wyden noted the company suffered a 2020 pretax loss in the US of $4.5 billion and an overseas pretax profit of $7.9 billion the same year. The report, released in July 2022, showed that AbbVie was able to dodge U.S. taxes by registering intellectual property in offshore jurisdictions such as Bermuda. As a result, while AbbVie received 75% of its sales of Humira in the United States, it only reported 1% of that income for U.S. tax purposes.
Marketing of opioid painkillers
In July 2022 the company agreed to pay up to $2.37 billion to settle U.S. lawsuits against its Allergan unit over the marketing of opioid analgesics. AbbVie denied any wrongdoing.
Litigation by the company against the NHS
In 2018, AbbVie sued NHS England in the Technology and Construction Court claiming that the agency breached procurement rules and had not treated the company fairly when seeking suppliers for hepatitis C treatments. In 2019, a UK court dismissed AbbVie's case against the NHS.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | ABBV | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 80.75Y avg ≈54.7 | ≈54.7 | 25.7 | Overvalued |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | ABBV | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | 26.2%5Y avg ≈25.5% | ≈25.5% | 30.1% | Top tier | |
| EBITDA Margin | 24.6%5Y avg ≈25.5% | ≈25.5% | 30.1% | Top tier | |
| Pretax Margin (TTM) | 13.5%5Y avg ≈15.0% | ≈15.0% | 25.2% | In line | |
| Net Profit Margin (TTM) | 9.8%5Y avg ≈12.9% | ≈12.9% | 21.3% | In line | |
| ROA (TTM) | 4.6%5Y avg ≈5.2% | ≈5.2% | 8.5% | Weak | |
| ROE (TTM) | -206.3%5Y avg ≈3123.7% | ≈3123.7% | 22.1% | Top tier | |
| ROIC | -1254.6%5Y avg ≈-129.2% | ≈-129.2% | 9.3% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | ABBV | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | -0.05Y avg ≈-0.2 | ≈-0.2 | 0.1 | Low debt | |
| Current Ratio (MRQ) | 0.85Y avg ≈0.8 | ≈0.8 | 2.3 | Low liquidity | |
| Quick Ratio | 0.45Y avg ≈0.5 | ≈0.5 | 0.8 | Low liquidity | |
| Interest Coverage | 5.25Y avg ≈5.9 | ≈5.9 | 6.6 | Low liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | ABBV | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 8.6%5Y avg ≈6.4% | ≈6.4% | · | · | |
| Revenue CAGR 3Y | 1.8%5Y avg ≈2.6% | ≈2.6% | · | · | |
| Revenue CAGR 5Y | 5.9% | · | · | · | |
| EPS YoY | -1.3%5Y avg ≈13.5% | ≈13.5% | · | · | |
| Net Income YoY | -1.2%5Y avg ≈16.1% | ≈16.1% | · | · | |
| EPS CAGR 3Y | -29.1%5Y avg ≈-19.1% | ≈-19.1% | · | · | |
| EPS CAGR 5Y | -2.8% | · | · | · | |
| Net Income CAGR 3Y | -29.1%5Y avg ≈-18.5% | ≈-18.5% | · | · | |
| Net Income CAGR 5Y | -1.8% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | ABBV | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.55Y avg ≈0.4 | ≈0.4 | 0.5 | In line | |
| Inventory Turnover | 4.05Y avg ≈4.8 | ≈4.8 | 3.6 | Top tier | |
| Receivables Turnover | 5.25Y avg ≈5.3 | ≈5.3 | 6.3 | Weak | |
| Revenue / Employee | ≈$1.1M | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Oct 15, 2026 | $1.73 | USD | ≈2.4% |
| Jul 15, 2026 | $1.73 | USD | ≈2.8% |
| Apr 15, 2026 | $1.73 | USD | ≈3.2% |
| Jan 16, 2026 | $1.73 | USD | ≈3.1% |
| Oct 15, 2025 | $1.64 | USD | ≈2.9% |
| Jul 15, 2025 | $1.64 | USD | ≈3.5% |
| Apr 15, 2025 | $1.64 | USD | ≈3.6% |
| Jan 15, 2025 | $1.64 | USD | ≈3.7% |
| Oct 15, 2024 | $1.55 | USD | ≈3.2% |
| Jul 15, 2024 | $1.55 | USD | ≈3.6% |
| Apr 12, 2024 | $1.55 | USD | ≈3.7% |
| Jan 12, 2024 | $1.55 | USD | ≈3.7% |
| Oct 12, 2023 | $1.48 | USD | ≈4.0% |
| Jul 13, 2023 | $1.48 | USD | ≈4.4% |
| Apr 13, 2023 | $1.48 | USD | ≈3.6% |
| Jan 12, 2023 | $1.48 | USD | ≈3.8% |
| Oct 13, 2022 | $1.41 | USD | ≈3.9% |
| Jul 14, 2022 | $1.41 | USD | ≈3.7% |
| Apr 13, 2022 | $1.41 | USD | ≈3.4% |
| Jan 13, 2022 | $1.41 | USD | ≈4.0% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Jul 29, 2026 | $3.65 | $3.68 | -0.71% |
| March 31, 2026 | $2.65 | $2.65 | 0.18% | |
| Dec. 31, 2025 | $2.71 | $2.71 | 0.17% | |
| Sept. 30, 2025 | $1.86 | $1.81 | 2.7% | |
| June 30, 2025 | $2.97 | $2.94 | 0.95% | |
| March 31, 2025 | $2.46 | $2.43 | 1.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B | $22.86B | $19.96B | |
| Cost of Revenue | $18.20B | $16.90B | $20.41B | $17.41B | $17.45B | $15.39B | $7.44B | $7.72B | $7.04B | $5.83B | $4.50B | $4.43B | |
| SG&A Expense | $14.01B | $14.75B | $12.87B | $15.26B | $12.35B | $11.30B | $6.94B | $7.40B | $6.29B | $5.88B | $6.39B | $7.72B | |
| Operating Expenses | $46.09B | $47.20B | $41.56B | $39.94B | $38.27B | $34.44B | $20.28B | $26.37B | $18.67B | $16.30B | $15.32B | $16.55B | |
| Operating Income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B | $9.54B | $9.34B | $7.54B | $3.41B | |
| Interest Expense | $2.89B | $2.81B | $2.22B | $2.23B | $2.42B | $2.45B | $1.78B | $1.35B | $1.15B | $1.05B | $719M | $429M | |
| Other Non-op | $-5.79B | $-3.24B | $-4.68B | $-2.45B | $-2.50B | $-5.61B | $-3.01B | $-18M | $-466M | $-188M | $-13M | $27M | |
| Pretax Income | $6.60B | $3.72B | $6.25B | $13.48B | $12.99B | $3.40B | $8.43B | $5.20B | $7.73B | $7.88B | $6.64B | $2.37B | |
| Income Tax | $2.36B | $-570M | $1.38B | $1.63B | $1.44B | $-1.22B | $544M | $-490M | $2.42B | $1.93B | $1.50B | $595M | |
| Net Income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B | $5.14B | $1.77B | |
| EPS (Basic) | $2.37 | $2.40 | $2.73 | $6.65 | $6.48 | $2.73 | $5.30 | $3.67 | $3.31 | $3.65 | $3.15 | $1.11 | |
| EPS (Diluted) | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 | $3.66 | $3.30 | $3.63 | $3.13 | $1.10 | |
| Shares (Basic) | 1,769,000,000 | 1,769,000,000 | 1,768,000,000 | 1,771,000,000 | 1,770,000,000 | 1,667,000,000 | 1,481,000,000 | 1,541,000,000 | 1,596,000,000 | 1,622,000,000 | 1,625,000,000 | 1,595,000,000 | |
| Shares (Diluted) | 1,773,000,000 | 1,773,000,000 | 1,773,000,000 | 1,778,000,000 | 1,777,000,000 | 1,673,000,000 | 1,484,000,000 | 1,546,000,000 | 1,603,000,000 | 1,631,000,000 | 1,637,000,000 | 1,610,000,000 | |
| EBITDA | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B | $9.59B | $9.38B | $7.54B | $3.41B |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.23B | $5.52B | $12.81B | $9.20B | $9.75B | $8.45B | $39.92B | $7.29B | $9.30B | $5.10B | $8.40B | $8.35B | |
| Short-term Investments | $28M | $31M | $2M | $28M | $84M | $30M | $0 | $772M | $486M | $1.32B | $8M | $26M | |
| Receivables | $12.59B | $10.92B | $11.15B | $11.25B | $9.98B | $8.82B | $5.43B | $5.38B | $5.09B | $4.76B | $4.73B | · | |
| Inventory | $4.95B | $4.18B | $4.10B | $3.58B | $3.13B | $3.31B | $1.81B | $1.60B | $1.60B | $1.44B | $1.72B | $1.12B | |
| Prepaid Expense | $6.29B | · | · | · | · | · | · | · | · | · | · | · | |
| Current Assets | $29.06B | $25.58B | $33.00B | $28.46B | $27.93B | $24.17B | $49.52B | $16.95B | $21.22B | $16.19B | $16.31B | $16.08B | |
| PP&E (Net) | $5.63B | $5.13B | $4.99B | $4.93B | $5.11B | $5.25B | $2.96B | $2.88B | $2.80B | $2.60B | $2.56B | $2.48B | |
| PP&E (Gross) | $13.53B | $12.27B | $11.63B | $10.99B | $10.73B | $10.86B | $8.19B | $8.40B | $8.07B | $7.53B | $7.33B | $7.11B | |
| Accum. Depreciation | $7.90B | $7.13B | $6.65B | $6.05B | $5.62B | $5.61B | $5.23B | $5.51B | $5.27B | $4.92B | $4.77B | $4.62B | |
| Goodwill | $35.64B | $34.96B | $32.29B | $32.16B | $32.38B | $33.12B | $15.60B | $15.66B | $15.79B | $15.42B | $13.17B | $5.86B | |
| Intangibles | $52.64B | $60.07B | $55.61B | $67.44B | $75.95B | $82.88B | $18.65B | $21.23B | $27.56B | $28.90B | $19.71B | $1.51B | |
| Other Non-current Assets | $10.72B | $9.14B | $8.51B | $5.57B | $4.88B | $4.85B | $2.29B | $1.21B | $1.33B | $1.21B | $1.15B | $1.48B | |
| Total Assets | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B | $59.35B | $70.79B | $66.10B | $53.05B | $27.51B | |
| Accounts Payable | $34.73B | $2.94B | $3.69B | $2.93B | $2.88B | $2.28B | $1.45B | $1.55B | $1.47B | $1.41B | $1.60B | $1.40B | |
| Short-term Debt | $2.50B | $0 | $0 | $1M | $14M | $34M | $0 | $3.70B | $400M | $377M | $406M | $425M | |
| Current Liabilities | $43.29B | $38.75B | $37.84B | $29.54B | $35.19B | $28.66B | $15.59B | $17.24B | $16.64B | $9.78B | $10.89B | $11.39B | |
| Capital Leases | $689M | $697M | $735M | $754M | $713M | $832M | · | · | · | · | · | · | |
| Deferred Tax | $2.39B | $2.58B | $1.95B | $2.19B | $3.01B | $3.65B | $1.13B | $1.07B | $2.49B | $6.89B | $5.28B | $159M | |
| Other Non-current Liabilities | $32.57B | $30.13B | $32.33B | $30.66B | $28.70B | $27.61B | $17.60B | $1.31B | $1.24B | $1.16B | $844M | $990M | |
| Long-term Debt | $64.50B | $66.84B | $59.24B | $63.13B | $75.96B | $84.95B | $67.23B | · | · | · | · | · | |
| Total Debt | $2.50B | · | $0 | $1M | $14M | $34M | $0 | $3.70B | $400M | $377M | $406M | $425M | |
| Retained Earnings | $-15.49B | $-7.90B | $-1.00B | $4.78B | $3.13B | $1.05B | $4.72B | $3.37B | $5.46B | $4.38B | $2.25B | $535M | |
| Treasury Stock | $9.15B | $8.20B | $6.53B | $4.59B | $3.14B | $2.26B | $24.50B | $24.11B | $11.92B | $10.85B | $8.84B | $972M | |
| AOCI | $-1.14B | $-1.93B | $-2.31B | $-2.20B | $-2.90B | $-3.12B | $-3.60B | $-2.48B | $-2.73B | $-2.59B | $-2.56B | $-2.03B | |
| Stockholders' Equity | $-3.27B | $3.33B | $10.36B | $17.25B | $15.41B | $13.08B | $-8.17B | $-8.45B | $5.10B | $4.64B | $3.94B | $1.74B | |
| Liabilities + Equity | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B | $59.35B | $70.79B | $66.10B | $53.05B | $27.51B |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $955M | $911M | $747M | $671M | $692M | $753M | $430M | $421M | $365M | $353M | $282M | $241M | |
| Deferred Tax | $-492M | $-1.45B | $-2.89B | $-1.93B | $-898M | $-2.33B | $122M | $-1.52B | $-4.16B | $-796M | $152M | $-380M | |
| Amort. of Intangibles | $7.38B | $7.62B | $7.95B | $7.69B | $7.72B | $5.80B | $1.55B | $1.29B | $1.08B | $764M | $419M | $403M | |
| Restructuring | · | · | · | · | · | · | $219M | $59M | $86M | $52M | $126M | $16M | |
| Operating Cash Flow | $19.03B | $18.81B | $22.84B | $24.94B | $22.78B | $17.59B | $13.32B | $13.43B | $9.96B | $7.04B | $7.54B | $3.55B | |
| CapEx | $1.21B | $974M | $777M | $695M | $787M | $798M | $552M | $638M | $529M | $479M | $532M | $612M | |
| Investing Cash Flow | $-6.64B | $-20.82B | $-2.01B | $-623M | $-2.34B | $-37.56B | $596M | $-1.01B | $-274M | · | · | · | |
| Debt Issued | $3.99B | $16.96B | · | $2.00B | $1.00B | $3.00B | $31.48B | $5.96B | $0 | $11.63B | $20.66B | · | |
| Net Debt Issued | $3.99B | $16.96B | · | $2.00B | $1.00B | $3.00B | $31.48B | $5.96B | $0 | $11.63B | $20.66B | · | |
| Stock Repurchased | $980M | $1.71B | $1.97B | $1.49B | $934M | $978M | $629M | $12.01B | $1.41B | $6.03B | $7.59B | $665M | |
| Net Stock Activity | $-980M | $-1.71B | $-1.97B | $-1.49B | $-934M | $-978M | $-629M | $-12.01B | $-1.41B | $-6.03B | $-7.57B | $-652M | |
| Dividends Paid | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B | $7.72B | $6.37B | $5.58B | $4.11B | $3.72B | $3.29B | $2.66B | |
| Financing Cash Flow | $-12.72B | $-5.21B | $-17.22B | $-24.80B | $-19.04B | $-11.50B | $18.71B | $-14.40B | $-5.51B | $-3.93B | · | · | |
| Net Change in Cash | $-295M | $-7.29B | $3.61B | $-545M | $1.30B | $-31.48B | $32.63B | $-2.01B | $4.20B | $-3.30B | $51M | $-1.25B | |
| Taxes Paid | $3.63B | $4.10B | $4.70B | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B | $16.79B | $12.77B | $12.79B | $9.43B | $6.56B | $7.00B | $2.94B | |
| Levered FCF | $15.96B | $14.59B | $20.33B | $22.29B | $19.84B | $13.45B | $11.10B | $11.31B | $8.64B | $5.77B | $6.45B | $2.62B |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 34.0% | 36.6% | 33.0% | 17.1% | |
| Net Margin | 6.9% | 7.6% | 8.9% | 20.4% | 20.5% | 10.1% | 23.7% | 17.4% | 18.8% | 23.2% | · | · | |
| Pretax Margin | 10.8% | 6.6% | 11.5% | 23.2% | 23.1% | 7.4% | 25.3% | 15.9% | 27.4% | 30.8% | 29.1% | 11.9% | |
| EBITDA Margin | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 34.0% | 36.6% | 33.0% | 17.1% | |
| ROA | 3.1% | 3.2% | 3.6% | 8.3% | 7.8% | 3.9% | 10.6% | 8.7% | 7.8% | 10.0% | · | · | |
| ROE | 15367.3% | 62.5% | 35.2% | 72.5% | 81.0% | 188.2% | -94.2% | -100.1% | 109.1% | 138.8% | · | · | |
| ROIC | -1254.6% | 317.0% | 96.0% | 92.3% | 103.3% | 117.9% | -148.6% | -147.1% | 119.9% | 141.3% | 134.1% | 117.9% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.7 | 0.7 | 0.9 | 1.0 | 0.8 | 0.8 | 3.2 | 1.0 | 1.3 | 1.7 | 1.5 | 1.4 | |
| Quick Ratio | 0.4 | 0.4 | 0.6 | 0.7 | 0.6 | 0.6 | 2.9 | 0.8 | 0.6 | 0.7 | 0.8 | 0.7 | |
| Debt / Equity | -0.8 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.4 | 0.1 | 0.1 | 0.1 | 0.2 | |
| Interest Coverage | 5.2 | 3.3 | 5.7 | 8.1 | 7.4 | 4.6 | 7.3 | 4.7 | 8.3 | 9.0 | 10.5 | 8.0 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.6 | 0.7 | |
| Inventory Turnover | 4.0 | 4.1 | 5.3 | 5.2 | 5.4 | 6.0 | 4.4 | 4.8 | 4.6 | 3.7 | 3.2 | 3.9 | |
| Receivables Turnover | 5.2 | 5.1 | 4.8 | 5.5 | 6.0 | 6.4 | 6.2 | 6.3 | · | · | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $34.50 | $31.77 | $30.64 | $32.65 | $31.62 | $27.38 | $22.42 | $21.19 | $17.60 | $15.72 | $13.96 | $12.40 | |
| Cash Flow / Share | $10.73 | $10.61 | $12.88 | $14.03 | $12.82 | $10.51 | $8.98 | $8.69 | $6.21 | $4.32 | $4.60 | $2.20 | |
| Dividend / Share | $6.65 | $6.29 | $5.99 | $5.71 | $5.31 | $4.84 | $4.39 | $3.95 | $2.63 | $2.35 | $2.10 | $1.75 | |
| Dividend Paid / Share | · | · | · | · | · | · | · | $3.95 | $2.63 | $2.35 | · | · | |
| EPS (TTM) | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 | $3.66 | $3.30 | $3.63 | $3.13 | $1.10 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 8.6% | 3.7% | -6.4% | 3.3% | 22.7% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 1.8% | 0.08% | 5.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 5.9% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -1.3% | -12.1% | -59.0% | 2.8% | 137.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -29.1% | -28.2% | 0.00% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -2.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -1.2% | -12.0% | -58.9% | 2.5% | 150.0% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -29.1% | -28.2% | 1.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -1.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 8.6% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B | $22.86B | $19.96B | |
| Net Income TTM | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B | $5.14B | $1.77B | |
| P/E | 96.8 | 74.4 | 57.0 | 24.4 | 21.0 | 39.4 | 16.8 | 25.2 | 29.3 | 17.3 | 18.9 | 59.5 | |
| Earnings Yield | 1.0% | 1.3% | 1.8% | 4.1% | 4.8% | 2.5% | 6.0% | 4.0% | 3.4% | 5.8% | 5.3% | 1.7% | |
| Payout Ratio | 275.8% | 257.7% | 216.7% | 84.9% | 80.2% | 167.2% | 80.8% | 98.1% | 77.4% | 62.4% | · | · | |
| Annual Payout | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B | $7.72B | $6.37B | $5.58B | $4.11B | $3.72B | $3.29B | $2.66B |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.99B | $15.00B | $16.62B | $15.78B | $15.42B | $13.34B | $15.10B | $14.46B | $14.46B | $12.31B | $14.30B | $13.93B | $13.87B | $12.22B | $15.12B | $14.81B | |
| Cost of Revenue | $4.29B | $4.22B | $4.55B | $5.30B | $4.35B | $4.00B | $4.40B | $4.21B | $4.20B | $4.09B | $5.70B | $6.49B | $4.24B | $3.99B | $4.17B | $5.02B | |
| Gross Profit | · | · | $12.07B | · | · | · | $10.71B | · | · | · | $8.60B | · | · | · | $10.95B | · | |
| SG&A Expense | $3.63B | $3.58B | $3.90B | $3.57B | $3.25B | $3.29B | $3.85B | $4.21B | $3.38B | $3.31B | $3.19B | $3.37B | $3.27B | $3.04B | $3.42B | $3.30B | |
| Operating Expenses | $10.56B | $11.01B | $12.07B | $13.87B | $10.53B | $9.61B | $16.59B | $10.63B | $10.46B | $9.51B | $11.11B | $11.65B | $9.35B | $9.46B | $9.62B | $10.21B | |
| Operating Income | $6.43B | $3.99B | $4.54B | $1.90B | $4.89B | $3.73B | $-1.49B | $3.83B | $4.00B | $2.80B | $3.19B | $2.28B | $4.51B | $2.77B | $5.50B | $4.60B | |
| Interest Expense | $746M | $717M | $714M | $739M | $740M | $700M | $702M | $720M | $726M | $660M | $564M | $555M | $552M | $553M | $566M | $560M | |
| Interest Income | $67M | $72M | · | $72M | $62M | $73M | · | $129M | $220M | $207M | · | $157M | $98M | $99M | · | $63M | |
| Other Non-op | $-1.48B | $-2.31B | $-1.21B | $-503M | $-2.66B | $-1.45B | $-150M | $-1.16B | $-1.34B | $-586M | $-1.56B | $95M | $-1.41B | $-1.80B | $-2.02B | $330M | |
| Pretax Income | $4.28B | $1.04B | $2.67B | $714M | $1.55B | $1.66B | $-2.27B | $2.08B | $2.15B | $1.75B | $1.21B | $1.95B | $2.61B | $475M | $2.96B | $4.40B | |
| Income Tax | $662M | $342M | $853M | $526M | $613M | $372M | $-2.25B | $520M | $773M | $383M | $388M | $172M | $583M | $234M | $493M | $448M | |
| Net Income | $3.61B | $695M | $1.82B | $186M | $938M | $1.29B | $-22M | $1.56B | $1.37B | $1.37B | $822M | $1.78B | $2.02B | $239M | $2.47B | $3.95B | |
| EPS (Basic) | $2.04 | $0.39 | $1.02 | $0.10 | $0.52 | $0.72 | $-0.02 | $0.88 | $0.77 | $0.77 | $0.46 | $1.00 | $1.14 | $0.13 | $1.39 | $2.22 | |
| EPS (Diluted) | $2.03 | $0.39 | $1.02 | $0.10 | $0.52 | $0.72 | $-0.03 | $0.88 | $0.77 | $0.77 | $0.45 | $1.00 | $1.14 | $0.13 | $1.40 | $2.21 | |
| Shares (Basic) | 1,769,000,000 | 1,770,000,000 | · | 1,769,000,000 | 1,768,000,000 | 1,768,000,000 | · | 1,769,000,000 | 1,768,000,000 | 1,769,000,000 | · | 1,767,000,000 | 1,767,000,000 | 1,770,000,000 | · | 1,771,000,000 | |
| Shares (Diluted) | 1,771,000,000 | 1,774,000,000 | · | 1,772,000,000 | 1,771,000,000 | 1,772,000,000 | · | 1,772,000,000 | 1,771,000,000 | 1,773,000,000 | · | 1,771,000,000 | 1,771,000,000 | 1,776,000,000 | · | 1,776,000,000 | |
| EBITDA | $6.43B | $3.99B | · | $1.90B | $4.89B | $3.73B | · | $3.83B | $4.00B | $2.80B | · | $2.28B | $4.51B | $2.77B | · | $4.60B |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.57B | $9.39B | $5.23B | $5.63B | $6.47B | $5.17B | $5.52B | $7.26B | $13.13B | $18.07B | · | $13.29B | $8.76B | $6.71B | · | $11.83B | |
| Short-term Investments | · | · | $28M | $42M | $0 | $1M | $31M | $28M | $27M | $2M | · | $3M | $7M | $11M | · | $47M | |
| Receivables | $13.82B | $12.48B | $12.59B | $12.77B | $12.64B | $12.48B | $10.92B | $11.47B | $11.72B | $11.95B | · | $11.41B | $11.49B | $11.47B | · | $10.74B | |
| Inventory | $5.13B | $5.05B | $4.95B | $4.94B | $4.96B | $4.53B | $4.18B | $4.45B | $4.22B | $4.25B | · | $3.98B | $4.05B | $3.83B | · | $3.17B | |
| Prepaid Expense | $8.15B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Assets | $33.67B | $33.53B | $29.06B | $28.54B | $29.26B | $27.68B | $25.58B | $27.79B | $33.82B | $38.87B | · | $33.22B | $28.85B | $26.49B | · | $30.36B | |
| PP&E (Net) | $5.80B | $5.69B | $5.63B | $5.48B | $5.28B | $5.24B | $5.13B | $5.14B | $5.02B | $4.98B | · | $4.93B | $4.94B | $4.93B | · | $4.89B | |
| PP&E (Gross) | $13.96B | $13.73B | $13.53B | $13.23B | $12.93B | $12.57B | $12.27B | $12.28B | $11.90B | $11.72B | · | $11.37B | $11.32B | $11.14B | · | $10.68B | |
| Accum. Depreciation | $8.16B | $8.04B | $7.90B | $7.75B | $7.65B | $7.33B | $7.13B | $7.14B | $6.88B | $6.75B | · | $6.44B | $6.38B | $6.21B | · | $5.79B | |
| Goodwill | $35.52B | $35.57B | $35.64B | $35.63B | $35.64B | $35.28B | $34.96B | $35.30B | $33.39B | $33.43B | $32.29B | $32.09B | $32.22B | $32.22B | $32.16B | $31.73B | |
| Intangibles | $49.14B | $50.87B | $52.64B | $54.31B | $57.03B | $58.49B | $60.07B | $66.65B | $60.24B | $62.23B | · | $58.60B | $62.86B | $64.85B | · | $68.72B | |
| Other Non-current Assets | $10.73B | $10.54B | $10.72B | $9.64B | $9.66B | $9.19B | $9.14B | $8.29B | $9.20B | $9.07B | · | $7.09B | $6.20B | $5.80B | · | $5.38B | |
| Total Assets | $135.12B | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B | $135.16B | $143.42B | $141.94B | $148.87B | · | $136.22B | $135.37B | $134.54B | · | $141.32B | |
| Accounts Payable | $33.30B | $33.77B | $3.59B | $33.62B | $32.24B | $31.04B | $2.94B | $30.49B | $29.33B | $31.33B | · | $29.66B | $27.04B | $24.79B | · | $23.50B | |
| Short-term Debt | $0 | $0 | $2.50B | $3.79B | $5.56B | $1.59B | $0 | · | · | $3M | · | $2M | $0 | $1M | · | $10M | |
| Current Liabilities | $41.64B | $42.10B | $43.29B | $39.39B | $39.77B | $36.40B | $38.75B | $43.06B | $41.91B | $41.52B | · | $34.77B | $32.24B | $27.59B | · | $32.71B | |
| Capital Leases | · | · | $689M | · | · | · | $697M | · | · | · | · | · | · | · | · | · | |
| Deferred Tax | $2.28B | $2.33B | $2.39B | $2.48B | $2.55B | $2.58B | $2.58B | $2.75B | $2.73B | $2.72B | · | $2.04B | $2.12B | $2.11B | · | $1.97B | |
| Other Non-current Liabilities | $34.60B | $34.11B | $32.57B | $31.66B | $32.04B | $31.19B | $30.13B | $33.03B | $32.43B | $32.78B | · | $31.64B | $32.29B | $32.25B | · | $30.21B | |
| Long-term Debt | · | · | $64.50B | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $0 | $0 | · | $3.79B | $5.56B | $1.59B | · | · | · | $3M | · | $2M | $0 | $1M | · | $10M | |
| Retained Earnings | $-17.33B | $-17.87B | $-15.49B | $-14.23B | $-11.50B | $-9.53B | $-7.90B | $-4.96B | $-3.77B | $-2.38B | · | $933M | $1.79B | $2.39B | · | $4.95B | |
| Treasury Stock | $10.62B | $10.61B | $9.15B | $9.14B | $9.15B | $9.14B | $8.20B | $7.85B | $7.84B | $7.83B | · | $6.53B | $6.53B | $6.52B | · | $4.59B | |
| AOCI | $-1.16B | $-1.15B | $-1.14B | $-1.57B | $-1.54B | $-1.74B | $-1.93B | $-2.33B | $-2.51B | $-2.45B | · | $-2.35B | $-2.25B | $-2.23B | · | $-3.44B | |
| Stockholders' Equity | $-5.93B | $-6.66B | $-3.27B | $-2.64B | $-183M | $1.42B | $3.33B | $6.03B | $6.78B | $8.01B | · | $12.09B | $12.87B | $13.27B | · | $15.99B | |
| Liabilities + Equity | $135.12B | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B | $135.16B | $143.42B | $141.94B | $148.87B | · | $136.22B | $135.37B | $134.54B | · | $141.32B |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $166M | $444M | $157M | $209M | $179M | $410M | $164M | $181M | $218M | $348M | $125M | $130M | $179M | $313M | $132M | $126M | |
| Deferred Tax | $-195M | $137M | $-385M | $193M | $-272M | $-28M | $-767M | $-277M | $-16M | $-389M | $-1.39B | $-863M | $-368M | $-267M | $-516M | $-621M | |
| Amort. of Intangibles | $1.70B | $1.75B | $1.72B | $1.90B | $1.90B | $1.86B | $1.93B | $1.90B | $1.90B | $1.89B | $1.90B | $2.00B | $2.10B | $1.95B | $2.03B | $2.00B | |
| Operating Cash Flow | $3.44B | $3.83B | $5.22B | $7.02B | $5.15B | $1.64B | $7.05B | $5.45B | $2.27B | $4.04B | $4.75B | $7.57B | $6.32B | $4.19B | $7.43B | $7.60B | |
| CapEx | $322M | $265M | $329M | $381M | $269M | $235M | $291M | $249M | $241M | $193M | $205M | $219M | $178M | $175M | $213M | $177M | |
| Investing Cash Flow | $-1.20B | $-574M | $-1.46B | $-3.26B | $-1.18B | $-735M | $-1.87B | $-8.26B | $-1.10B | $-9.59B | $-800M | $-369M | $-341M | $-499M | $-448M | $1.29B | |
| Debt Issued | $0 | $7.99B | $0 | $0 | $0 | $3.99B | $2.00B | $0 | $0 | $14.96B | · | $0 | $0 | $0 | $0 | $0 | |
| Net Debt Issued | · | $7.99B | · | · | · | $3.99B | · | · | · | $14.96B | · | · | · | $0 | · | · | |
| Stock Repurchased | $9M | $1.49B | $3M | $4M | $12M | $961M | $358M | $17M | $9M | $1.32B | $3M | $4M | $10M | $1.96B | $4M | $4M | |
| Net Stock Activity | · | $-1.49B | · | · | · | $-961M | · | · | · | $-1.32B | · | · | · | $-1.96B | · | · | |
| Dividends Paid | $3.07B | $3.09B | $2.91B | $2.91B | $2.91B | $2.92B | $2.75B | $2.75B | $2.75B | $2.77B | $2.63B | $2.63B | $2.62B | $2.66B | $2.51B | $2.50B | |
| Financing Cash Flow | $-5.05B | $919M | $-4.17B | $-4.59B | $-2.71B | $-1.26B | $-6.86B | $-3.07B | $-6.10B | $10.82B | $-4.45B | $-2.66B | $-3.92B | $-6.19B | $-9.63B | $-5.52B | |
| Net Change in Cash | $-2.82B | $4.16B | $-400M | $-838M | $1.29B | $-349M | $-1.73B | $-5.87B | $-4.94B | $5.25B | $-473M | $4.53B | $2.05B | $-2.49B | $-2.63B | $3.31B | |
| Free Cash Flow | · | $3.56B | · | · | · | $1.40B | · | · | · | $3.85B | · | · | · | $4.02B | · | · | |
| Levered FCF | · | $3.08B | · | · | · | $857M | · | · | · | $3.33B | · | · | · | $3.74B | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 37.9% | 26.6% | · | 12.1% | 31.7% | 28.0% | · | 26.5% | 27.6% | 22.7% | · | 16.4% | 32.6% | 22.6% | · | 31.1% | |
| Net Margin | 21.3% | 4.6% | · | 1.2% | 6.1% | 9.6% | · | 10.8% | 9.5% | 11.1% | · | 12.8% | 14.6% | 2.0% | · | 26.7% | |
| Pretax Margin | 25.2% | 6.9% | · | 4.5% | 10.1% | 12.4% | · | 14.4% | 14.8% | 14.3% | · | 14.0% | 18.8% | 3.9% | · | 29.7% | |
| EBITDA Margin | 37.9% | 26.6% | · | 12.1% | 31.7% | 28.0% | · | 26.5% | 27.6% | 22.7% | · | 16.4% | 32.6% | 22.6% | · | 31.1% | |
| ROA | 2.6% | 0.51% | · | 0.13% | 0.67% | 0.90% | · | 1.1% | 0.99% | 0.97% | · | 1.3% | 1.5% | 0.17% | · | 2.7% | |
| ROE | -118.1% | -26.6% | · | 11.0% | 28.4% | 27.3% | · | 17.2% | 14.0% | 12.9% | · | 12.7% | 14.7% | 1.6% | · | 26.7% | |
| ROIC | -91.6% | -40.2% | · | 43.7% | 55.2% | 96.2% | · | 47.7% | 37.7% | 27.3% | · | 17.2% | 27.2% | 10.6% | · | 25.8% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.8 | 0.8 | · | 0.7 | 0.7 | 0.8 | · | 0.6 | 0.8 | 0.9 | · | 1.0 | 0.9 | 1.0 | · | 0.9 | |
| Quick Ratio | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.5 | · | 0.4 | 0.6 | 0.7 | · | 0.7 | 0.6 | 0.7 | · | 0.7 | |
| Debt / Equity | 0.0 | 0.0 | · | -1.4 | -30.4 | 1.1 | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Interest Coverage | 8.6 | 5.6 | · | 2.6 | 6.6 | 5.3 | · | 5.3 | 5.5 | 4.2 | · | 4.1 | 8.2 | 5.0 | · | 8.2 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.9 | 0.9 | · | 1.1 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.0 | · | 1.8 | 1.1 | 1.1 | · | 1.6 | |
| Receivables Turnover | 1.3 | 1.2 | · | 1.3 | 1.3 | 1.1 | · | 1.3 | 1.2 | 1.1 | · | 1.3 | 1.2 | 1.1 | · | 1.5 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $9.59 | $8.46 | · | $8.90 | $8.71 | $7.53 | · | $8.16 | $8.17 | $6.94 | · | $7.86 | $7.83 | $6.88 | · | $8.34 | |
| Cash Flow / Share | · | $2.16 | · | · | · | $0.92 | · | · | · | $2.28 | · | · | · | $2.36 | · | · | |
| Dividend / Share | $1.73 | $1.73 | $1.73 | $1.64 | $1.64 | $1.64 | $1.64 | $1.55 | $1.55 | $1.55 | $1.55 | $1.48 | $1.48 | $1.48 | $1.48 | $1.41 | |
| EPS (TTM) | $3.54 | $2.03 | · | $1.31 | $2.09 | $2.34 | · | $2.87 | $2.99 | $3.36 | · | $3.67 | $4.88 | $4.25 | · | $7.49 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $64.39B | $62.82B | · | $59.64B | $58.33B | $57.37B | · | $55.53B | $55.00B | $54.40B | · | $55.14B | $56.02B | $56.74B | · | $57.82B | |
| Net Income TTM | $6.31B | $3.63B | · | $2.39B | $3.76B | $4.20B | · | $5.12B | $5.34B | $5.99B | · | $6.51B | $8.69B | $7.58B | · | $13.41B | |
| P/E | 71.1 | 107.1 | · | 176.7 | 88.8 | 89.5 | · | 68.8 | 57.4 | 54.2 | · | 40.6 | 27.6 | 37.5 | · | 17.9 | |
| Earnings Yield | 1.4% | 0.93% | · | 0.57% | 1.1% | 1.1% | · | 1.5% | 1.7% | 1.8% | · | 2.5% | 3.6% | 2.7% | · | 5.6% | |
| Payout Ratio | · | 444.0% | · | · | · | 227.5% | · | · | · | 202.5% | · | · | · | 1113.4% | · | · | |
| Annual Payout | $11.98B | $11.82B | · | $11.50B | $11.34B | $11.18B | · | $10.90B | $10.78B | $10.65B | · | $10.42B | $10.30B | $10.18B | · | $9.85B |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B |
| Operating Margin % | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% |
| Net Income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B |
| Diluted EPS | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | -0.8 | · | 0.0 | 0.0 | 0.0 |
| Current Ratio | 0.7 | 0.7 | 0.9 | 1.0 | 0.8 |
| Quick Ratio | 0.4 | 0.4 | 0.6 | 0.7 | 0.6 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B |
Institutional owners (13F) 4,539 filers · $373.4B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 252 (+6 vs prior Q) | 104 (-71 vs prior Q) | 1,934 (+223 vs prior Q) | 1,546 (-163 vs prior Q) | +33.9M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $41,306,353,424 | 180,779,699 | 11.06% | Shares |
| BlackRock, Inc. | $37,617,263,993 | 149,488,412 | 10.07% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $29,038,274,101 | 115,396,098 | 7.78% | Shares |
| STATE STREET CORP | $20,784,645,667 | 82,596,748 | 5.57% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12,199,002,913 | 48,477,996 | 3.27% | Shares |
| JPMORGAN CHASE & CO | $12,171,988,269 | 47,862,796 | 3.26% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $11,805,227,357 | 46,998,433 | 3.16% | Shares |
| MORGAN STANLEY | $9,789,048,614 | 38,901,001 | 2.62% | Shares |
| Capital Research Global Investors | $7,574,798,407 | 30,101,551 | 2.03% | Shares |
| NORGES BANK | $6,430,543,942 | 25,554,538 | 1.72% | Shares |
| BANK OF AMERICA CORP /DE/ | $5,344,270,976 | 21,237,764 | 1.43% | Shares |
| FMR LLC | $5,227,515,471 | 20,773,786 | 1.40% | Shares |
| NORTHERN TRUST CORP | $5,173,327,604 | 20,558,447 | 1.39% | Shares |
| FRANKLIN RESOURCES INC | $5,013,985,356 | 19,925,232 | 1.34% | Shares |
| Capital World Investors | $4,826,436,854 | 19,178,966 | 1.29% | Shares |
| GOLDMAN SACHS GROUP INC | $4,099,625,714 | 16,291,630 | 1.10% | Shares |
| Capital International Investors | $3,936,357,038 | 15,638,631 | 1.05% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3,250,509,754 | 12,914,230 | 0.87% | Shares |
| Bank of New York Mellon Corp | $3,234,421,677 | 12,853,368 | 0.87% | Shares |
| UBS Group AG | $3,232,345,996 | 12,845,120 | 0.87% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $3,080,007,690 | 14,161,606 | 0.82% | Shares |
| Legal & General Group Plc | $2,905,952,066 | 11,548,053 | 0.78% | Shares |
| AMERIPRISE FINANCIAL INC | $2,900,213,433 | 11,519,507 | 0.78% | Shares |
| DEUTSCHE BANK AG\ | $2,710,904,889 | 10,772,949 | 0.73% | Shares |
| RAYMOND JAMES FINANCIAL INC | $2,619,612,537 | 10,410,159 | 0.70% | Shares |
| Amundi | $2,526,281,104 | 10,039,289 | 0.68% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $2,501,249,007 | 9,939,791 | 0.67% | Shares |
| Nuveen, LLC | $2,393,093,998 | 9,509,991 | 0.64% | Shares |
| Fisher Asset Management, LLC | $2,390,069,445 | 9,497,970 | 0.64% | Shares |
| WELLS FARGO & COMPANY/MN | $2,269,183,889 | 9,017,580 | 0.61% | Shares |
| ROYAL BANK OF CANADA | $2,054,341,000 | 8,163,806 | 0.55% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $1,821,124,683 | 7,236,861 | 0.49% | Shares |
| Invesco Ltd. | $1,790,363,623 | 7,114,782 | 0.48% | Shares |
| JANUS HENDERSON GROUP PLC | $1,507,338,150 | 6,931,036 | 0.40% | Shares |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | $1,482,866,205 | 5,892,808 | 0.40% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $1,272,188,414 | 5,055,589 | 0.34% | Shares |
| BARCLAYS PLC | $1,262,104,191 | 5,015,515 | 0.34% | Shares |
| Swiss National Bank | $1,255,358,984 | 4,988,710 | 0.34% | Shares |
| ENVESTNET ASSET MANAGEMENT INC | $1,229,678,938 | 4,886,670 | 0.33% | Shares |
| NORDEA INVESTMENT MANAGEMENT AB | $1,208,014,926 | 4,805,342 | 0.32% | Shares |
| Boston Partners | $1,202,518,364 | 4,784,316 | 0.32% | Shares |
| FEDERATED HERMES, INC. | $1,122,678,971 | 4,461,449 | 0.30% | Shares |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $1,110,959,915 | 4,388,338 | 0.30% | Shares |
| Mitsubishi UFJ Asset Management Co., Ltd. | $1,092,298,708 | 4,340,720 | 0.29% | Shares |
| HSBC HOLDINGS PLC | $1,040,184,766 | 4,131,637 | 0.28% | Shares |
| LPL Financial LLC | $1,030,798,580 | 4,096,323 | 0.28% | Shares |
| National Pension Service | $1,008,968,950 | 4,009,573 | 0.27% | Shares |
| PNC Financial Services Group, Inc. | $1,008,433,649 | 4,007,446 | 0.27% | Shares |
| VANGUARD ASSET MANAGEMENT, Ltd | $1,005,413,025 | 3,995,442 | 0.27% | Shares |
| Sumitomo Mitsui Trust Group, Inc. | $992,857,195 | 3,945,546 | 0.27% | Shares |
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| AbbVie Inc. | Oct. 6, 2017 | · | Initial filing | M&A / sale | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 39 insiders · 22 officers · 15 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Robert A. Michael | CHAIRMAN OF THE BOARD AND CEO | Feb. 27, 2026 F | 178,737 | 0 | 0 | $0 |
| Scott T Reents | EVP, CHIEF FINANCIAL OFFICER | Feb. 27, 2026 F | 38,777 | 0 | 0 | $0 |
| Nicholas Donoghoe | EVP, CHIEF BUS/STRAT OFFICER | Aug. 14, 2026 M | 74,430 | 0 | 1 | $-8,177,500 |
| Perry C Siatis | EVP, GC AND SECRETARY | March 2, 2026 S | 4,619 | 0 | 4 | $-9,523,179 |
| Demetris D Crum | EVP, CHIEF HR OFFICER | Feb. 27, 2026 F | 7,914 | 0 | 0 | $0 |
| David Ryan Purdue | SVP, Controller | Feb. 27, 2026 F | 8,468 | 0 | 1 | $-1,221,519 |
| Roopal Thakkar | EVP, R&D and CSO | Feb. 27, 2026 F | 52,376 | 0 | 0 | $0 |
| Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | Feb. 27, 2026 F | 83,171 | 0 | 0 | $0 |
| Azita Saleki-Gerhardt | EVP, CHIEF OPERATIONS OFFICER | Feb. 27, 2026 F | 197,794 | 0 | 0 | $0 |
| Timothy J. Richmond | EVP, CHIEF HR OFFICER | March 3, 2025 S | 6,130 | 0 | 0 | $0 |
| Kevin K Buckbee | SVP, CONTROLLER | Feb. 28, 2025 F | 7,797 | 0 | 0 | $0 |
| Thomas J Hudson | SVP, CSO, GLOBAL RESEARCH | Feb. 28, 2024 F | 107,267 | 0 | 0 | $0 |
| Carrie C Strom | SVP & PRES GLOBAL ALLERG AESTH | May 11, 2023 F | 28,024 | 0 | 0 | $0 |
| Elaine K. Sorg | SVP, US COMMERCIAL OPERATIONS | April 25, 2023 M | 35,330 | 0 | 0 | $0 |
| Brian L Durkin | VP, CONTROLLER | Feb. 28, 2023 F | 33,149 | 0 | 0 | $0 |
| Michael Severino | Vice Chairman | May 23, 2022 M | 152,103 | 0 | 0 | $0 |
| Henry O Gosebruch | EVP, Chief Strategy Officer | May 16, 2022 M | 41,623 | 0 | 0 | $0 |
| Laura J Schumacher | Vice Chairman | Feb. 25, 2022 F | 248,002 | 0 | 0 | $0 |
| Carlos Alban | Vice Chairman | Nov. 16, 2020 M | 114,899 | 0 | 0 | $0 |
| William J Chase | EVP, Finance & Administration | June 26, 2019 P | 169,552 | 0 | 0 | $0 |
| Thomas A. Hurwich | VP, Controller | Feb. 28, 2017 F | 62,329 | 0 | 0 | $0 |
| John M. Leonard | SVP, Chief Scientific Officer | March 15, 2013 M | 107,320 | 0 | 0 | $0 |
| Susan E Quaggin | Director | Sept. 30, 2026 A | 3,643 | 0 | 0 | $0 |
| Edward J Rapp | Director | Sept. 30, 2026 A | 45,964 | 0 | 0 | $0 |
| Jennifer L. Davis | Director | May 8, 2026 A | 3,643 | 0 | 0 | $0 |
| Melody B Meyer | Director | May 8, 2026 A | 17,616 | 0 | 0 | $0 |
| William H.L. Burnside | Director | May 8, 2026 A | 28,076 | 0 | 0 | $0 |
| Brett J Hart | Director | May 8, 2026 A | 20,590 | 0 | 0 | $0 |
| Frederick H Waddell | Director | May 8, 2026 A | 30,076 | 0 | 0 | $0 |
| Thomas J Falk | Director | May 8, 2026 A | 2,321 | 0 | 0 | $0 |
| Roxanne S Austin | Director | May 8, 2026 A | 39,576 | 0 | 0 | $0 |
| Robert J Alpern | Director | March 31, 2026 A | 35,646 | 0 | 0 | $0 |
| Glenn F Tilton | Director | May 9, 2025 A | 51,564 | 0 | 0 | $0 |
| Richard A Gonzalez | Director | March 31, 2025 G | 386,479 | 0 | 0 | $0 |
| Edward M Liddy | Director | March 31, 2022 A | 26,683 | 0 | 0 | $0 |
| Roy S Roberts | Director | May 8, 2015 A | 27,486 | 0 | 0 | $0 |
| ABBOTT LABORATORIES | 10% owner | Dec. 12, 2012 J | 0 | 0 | 0 | $0 |
| Rebecca B Roberts | · | May 8, 2026 A | 14,846 | 0 | 0 | $0 |
| Thomas C Freyman | · | May 8, 2026 A | 127,869 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 209 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 7.85% | 2,838 NS | July 31, 2026 | N-PORT |
| IYH · iShares Trust | 7.27% | 1,036,373 SH | Sept. 11, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 6.56% | 5,317,086 SH | Aug. 19, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 6.42% | 841,398 NS | July 31, 2026 | N-PORT |
| HDV · iShares Trust | 6.19% | 3,722,395 SH | Sept. 11, 2026 | Daily |
| PJP · Invesco Exchange-Traded Fund Trust | 5.88% | 115,924 SH | Oct. 23, 2026 | Daily |
| CURE · Direxion Shares ETF Trust | 5.08% | 34,766 NS | July 31, 2026 | N-PORT |
| IXJ · iShares Trust | 5.07% | 825,161 SH | Sept. 11, 2026 | Daily |
| FLAG · Global X Funds | 4.82% | 326 NS | July 31, 2026 | N-PORT |
| LCOW · Pacer Funds Trust | 4.75% | 4,895 NS | July 31, 2026 | N-PORT |
| FDV · Federated Hermes ETF Trust | 3.29% | 115,545 NS | July 31, 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 3.25% | 524 NS | July 31, 2026 | N-PORT |
| MEDI · Harbor ETF Trust | 3.09% | 5,079 NS | July 31, 2026 | N-PORT |
| QDEF · FlexShares Trust | 3.03% | 65,928 NS | July 31, 2026 | N-PORT |
| DGRO · iShares Trust | 3.02% | 5,092,684 SH | Sept. 11, 2026 | Daily |
| QDF · FlexShares Trust | 2.94% | 259,882 NS | July 31, 2026 | N-PORT |
| SNPV · DBX ETF Trust | 2.88% | 30,853 NS | Aug. 31, 2026 | N-PORT |
| ABFL · Abacus FCF ETF Trust | 2.85% | 59,784 NS | July 31, 2026 | N-PORT |
| PAYR · Federated Hermes ETF Trust | 2.78% | 6,332 NS | July 31, 2026 | N-PORT |
| GEND · Spinnaker ETF Series | 2.72% | 526 NS | July 31, 2026 | N-PORT |
| XT · iShares Trust | 2.45% | 373,158 SH | Sept. 11, 2026 | Daily |
| QLV · FlexShares Trust | 2.43% | 15,876 NS | July 31, 2026 | N-PORT |
| NUDV · Nushares ETF Trust | 2.14% | 4,283 NS | July 31, 2026 | N-PORT |
| MGV · VANGUARD WORLD FUND | 2.10% | 1,110,490 SH | Aug. 19, 2026 | Daily |
| FDIV · EA Series Trust | 2.08% | 4,854 NS | July 31, 2026 | N-PORT |
| ACVU · Hartford Funds Exchange-Traded Trust | 2.02% | 14,545 NS | July 31, 2026 | N-PORT |
| BSCQ · Invesco Exchange-Traded Self-Indexe… | 2.02% | 60,734,000 | Oct. 23, 2026 | Daily |
| VIG · VANGUARD SPECIALIZED FUNDS | 1.94% | 9,981,469 SH | Aug. 19, 2026 | Daily |
| NULV · Nushares ETF Trust | 1.89% | 165,856 NS | July 31, 2026 | N-PORT |
| VYM · VANGUARD WHITEHALL FUNDS | 1.85% | 7,067,444 SH | Aug. 19, 2026 | Daily |
| DIVB · iShares Trust | 1.79% | 142,660 SH | Sept. 11, 2026 | Daily |
| PFM · Invesco Exchange-Traded Fund Trust | 1.78% | 50,079 SH | Oct. 23, 2026 | Daily |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.74% | 58,678 SH | Oct. 23, 2026 | Daily |
| FTLS · First Trust Exchange-Traded Fund III | 1.74% | 172,391 NS | July 31, 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 1.69% | 54,073,000 | Oct. 23, 2026 | Daily |
| VTV · VANGUARD INDEX FUNDS | 1.66% | 16,798,484 SH | Aug. 19, 2026 | Daily |
| WCAP · Spinnaker ETF Series | 1.64% | 3,990 NS | July 31, 2026 | N-PORT |
| KNG · First Trust Exchange-Traded Fund IV | 1.62% | 228,681 NS | July 31, 2026 | N-PORT |
| ALRG · ALLSPRING EXCHANGE-TRADED FUNDS TRU… | 1.59% | 532 NS | July 31, 2026 | N-PORT |
| SNPG · DBX ETF Trust | 1.58% | 878 NS | Aug. 31, 2026 | N-PORT |
| JDIV · J.P. Morgan Exchange-Traded Fund Tr… | 1.58% | 811 NS | July 31, 2026 | N-PORT |
| OEI · Listed Funds Trust | 1.55% | 2,864 NS | July 31, 2026 | N-PORT |
| IWX · iShares Trust | 1.54% | 235,248 SH | Sept. 11, 2026 | Daily |
| EVUS · iShares Trust | 1.49% | 22,181 SH | Sept. 11, 2026 | Daily |
| VUS · Virtus ETF Trust II | 1.48% | 1,056 NS | July 31, 2026 | N-PORT |
| JOYT · J.P. Morgan Exchange-Traded Fund Tr… | 1.41% | 5,472 NS | July 31, 2026 | N-PORT |
| JGLO · J.P. Morgan Exchange-Traded Fund Tr… | 1.40% | 370,528 NS | July 31, 2026 | N-PORT |
| FDRR · FIDELITY COVINGTON TRUST | 1.39% | 40,713 NS | July 31, 2026 | N-PORT |
| SNPD · DBX ETF Trust | 1.38% | 165 NS | Aug. 31, 2026 | N-PORT |
| FLRG · FIDELITY COVINGTON TRUST | 1.37% | 15,882 NS | July 31, 2026 | N-PORT |
| CHRI · Global X Funds | 1.35% | 430 NS | July 31, 2026 | N-PORT |
| ILCV · iShares Trust | 1.31% | 68,754 SH | Sept. 11, 2026 | Daily |
| INFO · Harbor ETF Trust | 1.29% | 43,209 NS | July 31, 2026 | N-PORT |
| NULC · Nushares ETF Trust | 1.28% | 3,602 NS | July 31, 2026 | N-PORT |
| DSI · iShares Trust | 1.28% | 270,036 SH | Sept. 11, 2026 | Daily |
| JQUA · J.P. Morgan Exchange-Traded Fund Tr… | 1.24% | 407,751 NS | July 31, 2026 | N-PORT |
| XLG · Invesco Exchange-Traded Fund Trust | 1.22% | 499,671 SH | Oct. 23, 2026 | Daily |
| FDLO · FIDELITY COVINGTON TRUST | 1.16% | 65,557 NS | July 31, 2026 | N-PORT |
| BKDV · BNY Mellon ETF Trust II | 1.15% | 84,302 NS | July 31, 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 1.15% | 983,559 SH | Aug. 19, 2026 | Daily |
| FQAL · FIDELITY COVINGTON TRUST | 1.14% | 64,248 NS | July 31, 2026 | N-PORT |
| DIVD · EA Series Trust | 1.14% | 976 NS | July 31, 2026 | N-PORT |
| FVAL · FIDELITY COVINGTON TRUST | 1.14% | 60,255 NS | July 31, 2026 | N-PORT |
| EQWL · Invesco Exchange-Traded Fund Trust | 1.13% | 112,675 SH | Oct. 23, 2026 | Daily |
| IWD · iShares Trust | 1.12% | 3,620,451 SH | Sept. 11, 2026 | Daily |
| HELO · J.P. Morgan Exchange-Traded Fund Tr… | 1.11% | 204,016 NS | July 31, 2026 | N-PORT |
| SNPE · DBX ETF Trust | 1.10% | 126,962 NS | Aug. 31, 2026 | N-PORT |
| UPSD · ETF Series Solutions | 1.10% | 5,134 NS | July 31, 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 1.09% | 14,559 NS | July 31, 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 1.07% | 107,107 NS | July 31, 2026 | N-PORT |
| BIGY · Tidal Trust II | 1.07% | 2,325 NS | July 31, 2026 | N-PORT |
| MPLY · Strategy Shares | 1.06% | 674 NS | July 31, 2026 | N-PORT |
| HAPI · Harbor ETF Trust | 1.06% | 20,723 NS | July 31, 2026 | N-PORT |
| DUHP · Dimensional ETF Trust | 1.05% | 514,323 NS | July 31, 2026 | N-PORT |
| EGLE · Global X Funds | 1.03% | 90 NS | July 31, 2026 | N-PORT |
| FYEE · Fidelity Greenwood Street Trust | 0.99% | 8,650 NS | July 31, 2026 | N-PORT |
| ACVF · ETF Opportunities Trust | 0.96% | 5,854 NS | July 31, 2026 | N-PORT |
| OEF · iShares Trust | 0.94% | 746,937 SH | Sept. 11, 2026 | Daily |
| FHEQ · Fidelity Greenwood Street Trust | 0.89% | 33,045 NS | July 31, 2026 | N-PORT |
| FBUF · Fidelity Greenwood Street Trust | 0.88% | 836 NS | July 31, 2026 | N-PORT |
| LRGF · iShares Trust | 0.87% | 124,903 SH | Sept. 11, 2026 | Daily |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0.86% | 30,469,000 | Oct. 23, 2026 | Daily |
| USCL · iShares Trust | 0.84% | 93,511 SH | Sept. 11, 2026 | Daily |
| FXH · First Trust Exchange-Traded AlphaDE… | 0.84% | 35,205 NS | July 31, 2026 | N-PORT |
| MGC · VANGUARD WORLD FUND | 0.84% | 353,229 SH | Aug. 19, 2026 | Daily |
| ACIO · ETF Series Solutions | 0.84% | 78,510 NS | July 31, 2026 | N-PORT |
| TOPC · iShares Trust | 0.84% | 1,075 SH | Sept. 11, 2026 | Daily |
| VOOV · VANGUARD ADMIRAL FUNDS | 0.83% | 219,693 SH | Aug. 19, 2026 | Daily |
| ADME · ETF Series Solutions | 0.82% | 9,586 NS | July 31, 2026 | N-PORT |
| IVE · iShares Trust | 0.82% | 1,584,589 SH | Sept. 11, 2026 | Daily |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.81% | 133,875 SH | Oct. 23, 2026 | Daily |
| IWL · iShares Trust | 0.80% | 68,790 SH | Sept. 11, 2026 | Daily |
| VFMF · VANGUARD WELLINGTON FUND | 0.78% | 21,777 SH | Aug. 19, 2026 | Daily |
| IUSV · iShares Trust | 0.77% | 834,812 SH | Sept. 11, 2026 | Daily |
| PBP · Invesco Exchange-Traded Fund Trust | 0.77% | 10,596 SH | Oct. 23, 2026 | Daily |
| XVV · iShares Trust | 0.77% | 20,330 SH | Sept. 11, 2026 | Daily |
| ESGU · iShares Trust | 0.77% | 537,992 SH | Sept. 11, 2026 | Daily |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0.77% | 282,445 SH | Oct. 23, 2026 | Daily |
| LABU · Direxion Shares ETF Trust | 0.76% | 15,001 NS | July 31, 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0.76% | 400,307 SH | Aug. 19, 2026 | Daily |
| USMV · iShares Trust | 0.73% | 678,129 SH | Sept. 11, 2026 | Daily |
| COWG · Pacer Funds Trust | 0.72% | 63,118 NS | July 31, 2026 | N-PORT |
| VV · VANGUARD INDEX FUNDS | 0.70% | 2,063,411 SH | Aug. 19, 2026 | Daily |
| TOV · EA Series Trust | 0.70% | 7,329 NS | July 31, 2026 | N-PORT |
| GLOF · iShares Trust | 0.70% | 5,491 SH | Sept. 11, 2026 | Daily |
| XRMI · Global X Funds | 0.70% | 1,388 NS | July 31, 2026 | N-PORT |
| XYLD · Global X Funds | 0.70% | 89,923 NS | July 31, 2026 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0.69% | 45,894,828 SH | Aug. 19, 2026 | Daily |
| DFSU · Dimensional ETF Trust | 0.69% | 62,490 NS | July 31, 2026 | N-PORT |
| PTLC · Pacer Funds Trust | 0.69% | 89,516 NS | July 31, 2026 | N-PORT |
| XTR · Global X Funds | 0.69% | 132 NS | July 31, 2026 | N-PORT |
| XYLG · Global X Funds | 0.69% | 1,758 NS | July 31, 2026 | N-PORT |
| IVV · iShares Trust | 0.69% | 22,269,390 SH | Sept. 11, 2026 | Daily |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.69% | 243,537 NS | July 31, 2026 | N-PORT |
| BKLC · BNY Mellon ETF Trust | 0.68% | 149,142 NS | July 31, 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0.68% | 29,872 NS | July 31, 2026 | N-PORT |
| XCLR · Global X Funds | 0.68% | 97 NS | July 31, 2026 | N-PORT |
| ILCB · iShares Trust | 0.68% | 34,315 SH | Sept. 11, 2026 | Daily |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0.67% | 796 NS | July 31, 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.66% | 231,867 SH | Oct. 23, 2026 | Daily |
| VOXP · Advisors Series Trust | 0.65% | 150 NS | July 31, 2026 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.65% | 22,908 SH | Oct. 23, 2026 | Daily |
| PHDG · Invesco Actively Managed Exchange-T… | 0.65% | 1,392 SH | Oct. 23, 2026 | Daily |
| IWB · iShares Trust | 0.64% | 1,225,591 SH | Sept. 11, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.64% | 535,096 NS | July 31, 2026 | N-PORT |
| IYY · iShares Trust | 0.64% | 75,779 SH | Sept. 11, 2026 | Daily |
| RECS · Columbia ETF Trust I | 0.64% | 148,900 NS | July 31, 2026 | N-PORT |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.64% | 292,723 SH | Aug. 19, 2026 | Daily |
| SPUU · Direxion Shares ETF Trust | 0.63% | 6,666 NS | July 31, 2026 | N-PORT |
| IIGD · Invesco Exchange-Traded Self-Indexe… | 0.63% | 159,000 | Oct. 23, 2026 | Daily |
| QDPL · Pacer Funds Trust | 0.63% | 42,547 NS | July 31, 2026 | N-PORT |
| ESG · FlexShares Trust | 0.62% | 3,270 NS | July 31, 2026 | N-PORT |
| IWV · iShares Trust | 0.62% | 488,074 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.61% | 2,300,210 SH | Sept. 11, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.61% | 56,099,820 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.61% | 149,086 SH | Aug. 19, 2026 | Daily |
| APUE · Trust for Professional Managers | 0.61% | 58,813 NS | Aug. 31, 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0.60% | 17,034,000 | Oct. 23, 2026 | Daily |
| IVW · iShares Trust | 0.58% | 1,733,440 SH | Sept. 11, 2026 | Daily |
| VOOG · VANGUARD ADMIRAL FUNDS | 0.58% | 603,900 SH | Aug. 19, 2026 | Daily |
| TILT · FlexShares Trust | 0.56% | 48,980 NS | July 31, 2026 | N-PORT |
| IUSG · iShares Trust | 0.55% | 715,585 SH | Sept. 11, 2026 | Daily |
| DCOR · Dimensional ETF Trust | 0.55% | 73,443 NS | July 31, 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0.55% | 12,296 NS | July 31, 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0.54% | 18,022 SH | Aug. 19, 2026 | Daily |
| WSGE · EA Series Trust | 0.54% | 1,303 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.54% | 267,233 NS | July 31, 2026 | N-PORT |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0.53% | 704,000 | Oct. 23, 2026 | Daily |
| TOK · iShares Trust | 0.53% | 4,931 SH | Sept. 11, 2026 | Daily |
| RCGE · EA Series Trust | 0.53% | 2,130 NS | July 31, 2026 | N-PORT |
| KOKU · DBX ETF Trust | 0.52% | 16,567 NS | Aug. 31, 2026 | N-PORT |
| PEVC · Pacer Funds Trust | 0.52% | 50 NS | July 31, 2026 | N-PORT |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0.52% | 23,445,000 | Oct. 22, 2026 | Daily |
| SPXL · Direxion Shares ETF Trust | 0.52% | 138,128 NS | July 31, 2026 | N-PORT |
| URTH · iShares, Inc. | 0.50% | 159,211 SH | Sept. 11, 2026 | Daily |
| VLLU · Harbor ETF Trust | 0.48% | 89 NS | July 31, 2026 | N-PORT |
| CRBN · iShares Trust | 0.48% | 21,813 SH | Sept. 11, 2026 | Daily |
| ACWV · iShares, Inc. | 0.47% | 61,945 SH | Sept. 11, 2026 | Daily |
| FDVV · FIDELITY COVINGTON TRUST | 0.45% | 183,861 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.44% | 833,285 NS | July 31, 2026 | N-PORT |
| ACWI · iShares Trust | 0.44% | 563,215 SH | Sept. 11, 2026 | Daily |
| AFLG · First Trust Exchange-Traded Fund VI… | 0.42% | 12,525 NS | Aug. 31, 2026 | N-PORT |
| FBCG · FIDELITY COVINGTON TRUST | 0.42% | 114,618 NS | July 31, 2026 | N-PORT |
| DYNF · BlackRock ETF Trust | 0.41% | 664,980 SH | Sept. 11, 2026 | Daily |
| FTC · First Trust Exchange-Traded AlphaDE… | 0.39% | 20,427 NS | July 31, 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.38% | 1,481,748 SH | Aug. 19, 2026 | Daily |
| HDUS · Lattice Strategies Trust | 0.38% | 3,061 NS | July 31, 2026 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.36% | 6,632 NS | July 31, 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0.36% | 130,141 SH | Oct. 23, 2026 | Daily |
| DFVX · Dimensional ETF Trust | 0.35% | 7,418 NS | July 31, 2026 | N-PORT |
| GTO · Invesco Actively Managed Exchange-T… | 0.30% | 9,382,000 | Oct. 23, 2026 | Daily |
| JFLI · J.P. Morgan Exchange-Traded Fund Tr… | 0.30% | 566 NS | July 31, 2026 | N-PORT |
| VFMV · VANGUARD WELLINGTON FUND | 0.28% | 4,645 SH | Aug. 19, 2026 | Daily |
| ROUS · Lattice Strategies Trust | 0.25% | 7,097 NS | July 31, 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.23% | 5,034 NS | July 31, 2026 | N-PORT |
| RSP · Invesco Exchange-Traded Fund Trust | 0.22% | 782,448 SH | Oct. 23, 2026 | Daily |
| PWS · Pacer Funds Trust | 0.21% | 205 NS | July 31, 2026 | N-PORT |
| SIZE · iShares Trust | 0.21% | 3,448 SH | Sept. 11, 2026 | Daily |
| QLC · FlexShares Trust | 0.20% | 8,064 NS | July 31, 2026 | N-PORT |
| EUSA · iShares, Inc. | 0.20% | 14,673 SH | Sept. 11, 2026 | Daily |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.19% | 4,438 NS | July 31, 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0.18% | 11,199 NS | July 31, 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0.17% | 329 NS | July 31, 2026 | N-PORT |
| NPFE · Elevation Series Trust | 0.15% | 3,985 NS | July 31, 2026 | N-PORT |
| GTOS · Invesco Actively Managed Exchange-T… | 0.15% | 193,000 | Oct. 23, 2026 | Daily |
| IWY · iShares Trust | 0.13% | 77,600 SH | Sept. 11, 2026 | Daily |
| PABU · iShares Trust | 0.11% | 10,895 SH | Sept. 11, 2026 | Daily |
| VONG · VANGUARD SCOTTSDALE FUNDS | 0.11% | 223,700 SH | Aug. 19, 2026 | Daily |
| IWF · iShares Trust | 0.11% | 530,953 SH | Sept. 11, 2026 | Daily |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.10% | 2,954 SH | Oct. 22, 2026 | Daily |
| SPXD · DBX ETF Trust | 0.08% | 21 NS | Aug. 31, 2026 | N-PORT |
| ESMV · iShares Trust | 0.08% | 23 SH | Sept. 11, 2026 | Daily |
| NEAR · iShares U.S. ETF Trust | 0.05% | 2,690,000 SH | Sept. 11, 2026 | Daily |
| DEUS · DBX ETF Trust | 0.05% | 568 NS | Aug. 31, 2026 | N-PORT |
| FEUS · FlexShares Trust | 0.02% | 110 NS | July 31, 2026 | N-PORT |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BND · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| VUSB · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| VCRB · VANGUARD MALVERN FUNDS | · | · | July 15, 2026 | Daily |
| VPLS · VANGUARD MALVERN FUNDS | · | · | July 15, 2026 | Daily |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | July 30, 2026 | Daily |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | July 30, 2026 | Daily |
| BNDX · VANGUARD CHARLOTTE FUNDS | · | · | July 15, 2026 | Daily |
| VCEB · VANGUARD WORLD FUND | · | · | July 30, 2026 | Daily |
ABBV Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
28 analysts · 2026-10-20Mean target $282.61 -1.1%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| ABBV | · | 96.8 | 8.6% | 6.9% | 15367.3% | · |
| AMGN | $176.35B | 23.0 | 10.0% | 21.0% | 95.9% | · |
| GILD | $152.32B | 18.1 | 2.4% | 28.9% | 40.5% | · |
| VRTX | $115.15B | 29.6 | 8.9% | 32.9% | 22.1% | · |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | · |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | · |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | · |
Latest News Recent headlines mentioning this company
Trading Signals Recent buy/sell signals with entry price and risk/reward ratio
No open signal right now — no card is filled, and that's honest.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.